China Grants Priority Review for Biogen and Eisai's Alzheimer's Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy BIIB?
Source: stocktwits
- Priority Review Approval: China's drug regulator has granted Priority Review for Biogen and Eisai's Alzheimer's treatment Leqembi, which, if approved, would allow patients to self-administer a 250 mg dose weekly at home, significantly enhancing patient convenience and adherence to treatment.
- Significant Stock Surge: Following the announcement, Biogen's stock jumped 9% to close at $201.18, marking its highest level in over 16 months, reflecting strong market confidence in the company's future growth potential.
- Analysts Raise Targets: After Biogen's Q4 earnings beat expectations, several analysts raised their price targets, with Citi increasing its target to $215, implying a 7% upside, indicating optimism about the company's ability to launch new products successfully.
- Strong Market Sentiment: On Stocktwits, retail sentiment for BIIB is described as 'extremely bullish', with users highlighting the stock's characteristics as a high-quality large-cap biotech, suggesting it has the potential for further price increases in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 195.500
Low
143.00
Averages
204.45
High
246.00
Current: 195.500
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Elects New Chair of the Board
- Board Leadership Change: Biogen has elected Dr. Maria C. Freire as Chair of the Board, succeeding the retiring Caroline Dorsa, marking a pivotal transition for the company post-2026 Annual Meeting, which is expected to drive ongoing strategic development.
- New Chair's Background: Dr. Freire, who joined the Biogen Board in 2021, brings extensive experience in biomedical innovation and drug development, and is anticipated to leverage her expertise to guide the company through several key project advancements in the next 18 months, including potential filings in lupus and nephrology.
- Former Chair's Contributions: Caroline Dorsa's 16-year tenure on the Board has significantly enhanced innovation and shareholder value, and Dr. Freire's succession is viewed as a natural choice at a critical juncture for the company's transformation and growth, aiming to maintain and strengthen its competitive edge in the biopharmaceutical industry.
- Future Outlook: Under Dr. Freire's leadership, Biogen plans to continue advancing its sustainable growth strategy, particularly in new drug development and market expansion, which is expected to create long-term value for shareholders while addressing public health challenges.
See More
Biogen Elects Dr. Maria C. Freire as New Chair of the Board
- Board Leadership Change: Biogen has elected Dr. Maria C. Freire as the new Chair of the Board, succeeding the retiring Caroline Dorsa, marking a pivotal transition for the company following the 2026 Annual Meeting, which is expected to drive ongoing strategic development.
- Dorsa's Contributions: Caroline Dorsa has served on Biogen's Board for 16 years, during which she has advanced innovative drug development and enhanced shareholder value, fostering a culture of transparency and trust that lays a solid foundation for future leadership transitions.
- Freire's Background: The new Chair, Dr. Freire, brings extensive experience in biomedical innovation and drug development, having held leadership roles in several key organizations, and her expertise is expected to provide crucial support for Biogen's long-term growth and sustainability.
- Future Outlook: Dr. Freire noted that Biogen is at a critical growth juncture, with multiple clinical trial readouts anticipated in the next 18 months, including potential filings in lupus and nephrology, signaling new opportunities for the company.
See More
Biogen Reports Q4 and Full Year 2025 Earnings Exceeding Expectations
- Strong Financial Performance: Biogen's quarterly and full-year earnings for 2025 exceeded market expectations, indicating robust growth potential in the biopharmaceutical sector.
- Positive Market Reaction: The exceeding financial results are likely to drive Biogen's stock price upward, enhancing investor confidence and attracting more capital inflows.
- Clear Strategic Direction: The company highlighted future R&D investment plans in its earnings report, aiming to solidify its market position through innovative drug development and drive long-term growth.
- Enhanced Competitive Advantage: The better-than-expected performance not only reflects Biogen's operational efficiency but may also allow it to capture a larger market share in the highly competitive biopharmaceutical landscape.
See More
Biogen Reports Better-Than-Expected Q4 Results
- Strong Q4 Performance: Biogen's reported Q4 2025 revenues and earnings exceeded expectations, although the management's effective cost realignment highlights that revenue growth remains a critical missing piece in the turnaround narrative.
- Analyst Rating Adjustments: Wedbush's Laura Chico maintained a Neutral rating while raising the price target from $178 to $187, whereas HC Wainwright's Andrew Fein reiterated a Buy rating and increased the target from $194 to $228.
- New Product Sales: In 2025, Biogen's newer products (Leqembi, Skyclarys, Zurzuvae, Qalsody) generated approximately $980 million in sales, but total sales are expected to decline by about $500 million in 2026 due to competitive and generic threats to the MS franchise.
- Clinical Catalyst Outlook: Analysts noted that Biogen will have a stronger catalyst lineup in 2026, including Phase 2 data for BIIB091 in Q2 and readouts for BIIB122 and BIIB080, particularly highlighting the felzartamab program's 82% resolution rate in Phase 2, which could significantly impact future valuations.
See More
Biogen Reports Strong Q4 Earnings, Beats Expectations
- Earnings Beat: Biogen reported an adjusted EPS of $1.99 for Q4, surpassing the consensus estimate of $1.59, indicating strong execution and financial discipline.
- Revenue Performance: The company generated revenues of $2.28 billion, exceeding expectations of $2.20 billion, despite a 7% year-over-year decline, reflecting its competitive position in the Alzheimer's drug market.
- Future Outlook: Biogen anticipates fiscal 2026 earnings between $15.25 and $16.25 per share, above the consensus of $14.92, demonstrating confidence in future performance amid expected revenue declines.
- Analyst Rating Changes: Following the earnings announcement, several analysts adjusted their price targets for Biogen, with Piper Sandler raising its target from $157 to $177 and HC Wainwright & Co. increasing its target from $194 to $228, reflecting optimism about the company's future prospects.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific stock names are not mentioned, such rating changes typically lead to price fluctuations in the affected stocks, prompting investors to closely monitor these adjustments for portfolio optimization.
- Market Reaction Expectations: Analyst rating adjustments may trigger short-term market reactions, especially when investor sentiment is sensitive towards certain stocks, thereby impacting overall market sentiment.
- Information Access Channels: Investors can access a comprehensive view of rating changes through Benzinga's analyst ratings page, enabling them to make more informed investment decisions.
See More
Biogen Elects New Chair of the Board
- Board Leadership Change: Biogen has elected Dr. Maria C. Freire as Chair of the Board, succeeding the retiring Caroline Dorsa, marking a pivotal transition for the company post-2026 Annual Meeting, which is expected to drive ongoing strategic development.
- New Chair's Background: Dr. Freire, who joined the Biogen Board in 2021, brings extensive experience in biomedical innovation and drug development, and is anticipated to leverage her expertise to guide the company through several key project advancements in the next 18 months, including potential filings in lupus and nephrology.
- Former Chair's Contributions: Caroline Dorsa's 16-year tenure on the Board has significantly enhanced innovation and shareholder value, and Dr. Freire's succession is viewed as a natural choice at a critical juncture for the company's transformation and growth, aiming to maintain and strengthen its competitive edge in the biopharmaceutical industry.
- Future Outlook: Under Dr. Freire's leadership, Biogen plans to continue advancing its sustainable growth strategy, particularly in new drug development and market expansion, which is expected to create long-term value for shareholders while addressing public health challenges.
See More
Biogen Elects Dr. Maria C. Freire as New Chair of the Board
- Board Leadership Change: Biogen has elected Dr. Maria C. Freire as the new Chair of the Board, succeeding the retiring Caroline Dorsa, marking a pivotal transition for the company following the 2026 Annual Meeting, which is expected to drive ongoing strategic development.
- Dorsa's Contributions: Caroline Dorsa has served on Biogen's Board for 16 years, during which she has advanced innovative drug development and enhanced shareholder value, fostering a culture of transparency and trust that lays a solid foundation for future leadership transitions.
- Freire's Background: The new Chair, Dr. Freire, brings extensive experience in biomedical innovation and drug development, having held leadership roles in several key organizations, and her expertise is expected to provide crucial support for Biogen's long-term growth and sustainability.
- Future Outlook: Dr. Freire noted that Biogen is at a critical growth juncture, with multiple clinical trial readouts anticipated in the next 18 months, including potential filings in lupus and nephrology, signaling new opportunities for the company.
See More
Biogen Reports Q4 and Full Year 2025 Earnings Exceeding Expectations
- Strong Financial Performance: Biogen's quarterly and full-year earnings for 2025 exceeded market expectations, indicating robust growth potential in the biopharmaceutical sector.
- Positive Market Reaction: The exceeding financial results are likely to drive Biogen's stock price upward, enhancing investor confidence and attracting more capital inflows.
- Clear Strategic Direction: The company highlighted future R&D investment plans in its earnings report, aiming to solidify its market position through innovative drug development and drive long-term growth.
- Enhanced Competitive Advantage: The better-than-expected performance not only reflects Biogen's operational efficiency but may also allow it to capture a larger market share in the highly competitive biopharmaceutical landscape.
See More
Biogen Reports Better-Than-Expected Q4 Results
- Strong Q4 Performance: Biogen's reported Q4 2025 revenues and earnings exceeded expectations, although the management's effective cost realignment highlights that revenue growth remains a critical missing piece in the turnaround narrative.
- Analyst Rating Adjustments: Wedbush's Laura Chico maintained a Neutral rating while raising the price target from $178 to $187, whereas HC Wainwright's Andrew Fein reiterated a Buy rating and increased the target from $194 to $228.
- New Product Sales: In 2025, Biogen's newer products (Leqembi, Skyclarys, Zurzuvae, Qalsody) generated approximately $980 million in sales, but total sales are expected to decline by about $500 million in 2026 due to competitive and generic threats to the MS franchise.
- Clinical Catalyst Outlook: Analysts noted that Biogen will have a stronger catalyst lineup in 2026, including Phase 2 data for BIIB091 in Q2 and readouts for BIIB122 and BIIB080, particularly highlighting the felzartamab program's 82% resolution rate in Phase 2, which could significantly impact future valuations.
See More
Biogen Reports Strong Q4 Earnings, Beats Expectations
- Earnings Beat: Biogen reported an adjusted EPS of $1.99 for Q4, surpassing the consensus estimate of $1.59, indicating strong execution and financial discipline.
- Revenue Performance: The company generated revenues of $2.28 billion, exceeding expectations of $2.20 billion, despite a 7% year-over-year decline, reflecting its competitive position in the Alzheimer's drug market.
- Future Outlook: Biogen anticipates fiscal 2026 earnings between $15.25 and $16.25 per share, above the consensus of $14.92, demonstrating confidence in future performance amid expected revenue declines.
- Analyst Rating Changes: Following the earnings announcement, several analysts adjusted their price targets for Biogen, with Piper Sandler raising its target from $157 to $177 and HC Wainwright & Co. increasing its target from $194 to $228, reflecting optimism about the company's future prospects.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific stock names are not mentioned, such rating changes typically lead to price fluctuations in the affected stocks, prompting investors to closely monitor these adjustments for portfolio optimization.
- Market Reaction Expectations: Analyst rating adjustments may trigger short-term market reactions, especially when investor sentiment is sensitive towards certain stocks, thereby impacting overall market sentiment.
- Information Access Channels: Investors can access a comprehensive view of rating changes through Benzinga's analyst ratings page, enabling them to make more informed investment decisions.
See More
